
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
July 7, 2009-Diamant Centre, Brussels, Belgium
EFGCP will hold an interactive one-day workshop on pro’s- and con’s of a single CTA, different stakeholders’ view points, needs, and expectations. Different options will be discussed and their potential impact on the ethical review process considered. Registration details and practical information are accessible on the






